Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T Therapy

▴ Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T Therapy
Tessa announced, EMA has granted PRiority MEdicines designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma

Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumours, today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).

PRIME is a program launched by EMA to optimize development plans and speed up evaluation of medicines that demonstrate major therapeutic advantage over existing treatments, or otherwise benefit patients without treatment options. Through this program, EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for accelerated evaluation by the agency.

"We are very pleased that EMA has acknowledged the potential Tessa's CD30 CAR-T therapy holds for patients with Hodgkin Lymphoma" said Jeffrey H. Buchalter, President and CEO of Tessa Therapeutics. "Having received RMAT designation from FDA during 2020, we now hope to work closely with regulatory agencies in both the United States and Europe to expedite clinical development and the registration path for this therapy."

The PRIME designation was granted by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center. These studies showed complete disappearance of tumour in ~60% of patients at the highest dose level with none of the serious toxicities that can be associated with several other CAR-T therapies. These results were published in Journal of Clinical Oncology (Ramos et al., 2020). Based on these data, Tessa plans to commence a multi-center pivotal study in the United States during 2021.

Europe accounts for approximately a quarter of the world's Hodgkin Lymphoma incidence. Tessa's pivotal trial will be recruiting patients from more than 20 cancer centers across the US and Europe including sites in Italy, Spain and Sweden. "CD30 CAR-Ts demonstrated excellent safety and efficacy data in heavily pre-treated R/R cHL patients. We look forward to collaborating with Tessa to further validate these impressive results in the pivotal trial." said Dr Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Italy.

Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics said "CD30 CAR-T therapy, with its promising efficacy and very limited toxicity, can meaningfully address current gaps that exist in the treatment of R/R cHL. We also are exploring the potential of this therapy in CD30 positive subtypes of Non-Hodgkin Lymphoma (NHL)." Tessa's Phase 1 clinical study for patients with relapsed / refractory CD30 positive NHL is open for enrollment in the United States.

Tags : #TessaTherapeutics #LatestNewsonTessaTherapeutics #LatestPharmaNews19thJan #LatestNewsonCancerTreatment #EuropeanMedicinesAgency #USFDA

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Prescribing Equality: Tackling Gender Disparities in India's Healthcare LeadershipDecember 07, 2023
Digitalizing Health: Generative AI's Impact Amplified by AWS Cloud in IndiaDecember 07, 2023
Eyes on the Future: Dr. Agarwal's Group Channels Rs 100 Crore for Cutting-edge Eye Hospitals Across KeralaDecember 06, 2023
Organ Transplant Scandal: Apollo Hospital Faces Government InquiryDecember 06, 2023
Breaking Barriers in Cancer Treatment: Max Healthcare's CAR-T Therapy PartnershipDecember 06, 2023
Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023